KIT and gastrointestinal stromal tumor: The imatinib‐resistant GIST cell line GIST430/654 (KIT exon 11 delV560‐L576) with a secondary KIT mutation (KIT exon 13 V654) and similar kinetics to GIST882 to induce tumors (Smyth et al., 2012) was used as an imatinib‐resistant model for tumor growth in vivo.